Founded with a mission to protect and preserve the gift of sight, executives from the newly created Sirion Therapeutics, Inc. unveiled their new company today. The announcement was made by co-founders Barry Butler, Chairman and Chief Executive Officer; Roger
Vogel, MD, Chief Medical Officer; Susan Benton, Chief Commercial Officer; and
Philippe Boulangeat, Chief Business Officer.
PR
Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Axonics Earns FDA Premarket Approval for Sacral Neuromodulation Device
Patients no longer need to have their neurostimulator explanted before they undergo the scan.
Recro Pharma Appeal of CRL for Non-Opioid Pain Product Granted
The FDA said it would work with the company on prescribing information.
FDAnews Drug Daily Bulletin
SIRION THERAPEUTICS SETS ITS SIGHTS ON OPHTHALMIC HEALTH
June 20, 2006
